We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current CPRX market cap is 2.77B. The company's latest EPS is USD 0.5987 and P/E is 38.73.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 102.69M | 110.57M | 98.51M | 122.71M | 128.7M |
| Operating Income | -37.19M | 41.69M | 27.13M | 54.25M | 50.91M |
| Net Income | -30.76M | 34.84M | 23.28M | 40.79M | 43.88M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 102.31M | 119.07M | 140.83M | 214.2M | 398.2M |
| Operating Income | 31.82M | 41.3M | 52.39M | 101.84M | 86.81M |
| Net Income | 31.88M | 74.98M | 39.48M | 83.08M | 71.41M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 413.21M | 470.11M | 646.68M | 706.36M | 772.01M |
| Total Liabilities | 64.66M | 82.23M | 85.26M | 97.71M | 111.07M |
| Total Equity | 348.55M | 387.88M | 561.41M | 608.66M | 660.94M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 112.38M | 192.35M | 237.79M | 375.63M | 470.11M |
| Total Liabilities | 24.75M | 22.76M | 30.96M | 75.21M | 82.23M |
| Total Equity | 87.63M | 169.6M | 206.83M | 300.42M | 387.88M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 87.95M | 143.6M | 31.93M | 96.06M | 168.93M |
| Investing | -255.18M | -293.5M | -199k | -209k | -468k |
| Financing | -10.19M | -10.86M | 141.05M | 142.21M | 136.23M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 34.61M | 45.04M | 60.37M | 116.05M | 143.6M |
| Investing | 37.23M | -5.01M | -11.02M | 9.21M | -293.5M |
| Financing | 1.12M | 701k | -8.14M | 1.69M | -10.86M |
| Market Cap | 2.77B |
| Price to Earnings Ratio | 38.73 |
| Price to Sales Ratio | 6.95 |
| Price to Cash Ratio | 20.1 |
| Price to Book Ratio | 7.13 |
| Dividend Yield | - |
| Shares Outstanding | 119.27M |
| Average Volume (1 week) | 909.99k |
| Average Volume (1 Month) | 1.56M |
| 52 Week Change | 57.65% |
| 52 Week High | 24.32 |
| 52 Week Low | 13.1161 |
| Spread (Intraday) | 1.45 (5.93%) |
| Company Name | Catalyst Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.catalystpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
